Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering, and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T-cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last.
Location: United States, Massachusetts, Watertown
Employees: 51-200
Total raised: $175M
Investors 5
| Date | Name | Website |
| - | Spur Capit... | spurcapita... |
| 25.03.2022 | Vida Ventu... | vidaventur... |
| 27.10.2023 | Jacket Riv... | jacketrive... |
| - | Humboldt | humboldtfu... |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.03.2022 | - | $175M | Vida Ventu... |
Mentions in press and media 11
| Date | Title | Description |
| 24.04.2025 | Affini-T Therapeutics Presents Preclinical Data from its Programs Targeting Oncogenic Drivers KRAS and TP53 at AACR | BOSTON, MA, UNITED STATES, April 24, 2025 /EINPresswire.com/ -- Affini-T Therapeutics to present data from pipeline programs targeting the cancer driver mutations KRAS G12V and TP53 R175H. Presentations will include real-world data on the l... |
| 20.07.2023 | Affini-T Therapeutics shutting down Seattle lab | Affini-T Therapeutics, a cell therapy company spun out of Fred Hutchinson Cancer Research Center that aims to treat solid tumors, is closing its Seattle lab. Multiple impacted employees posted on LinkedIn about the Seattle office shutting d... |
| 23.03.2022 | Affini-T Therapeutics Closes $175M Financing | Affini-T Therapeutics, a Boston, MA, and Seattle, WA-based biotechnology company, raised $175M in funding. The round was led by Vida Ventures and Leaps by Bayer, with participation from Humboldt Fund, The Parker Institute for Cancer Immunot... |
| 22.03.2022 | Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations | - |
| 22.03.2022 | Fred Hutch spinout Affini-T Therapeutics lands $175M for cell therapies to treat solid tumors | From left: Affini-T scientific co-founders and Fred Hutch investigators Philip Greenberg, Aude Chapuis, and Thomas Schmitt. (Fred Hutch Photos) New funding: Affini-T Therapeutics, a cell therapy company spun out of Fred Hutchinson Cancer Re... |
| 22.03.2022 | Bayer-backed Affini-T snags $175M to enter increasingly crowded KRAS-cancer field | Affini-T Therapeutics CEO Jak Knowles, M.D., is no stranger to the kind of startups that draw early capital, having once been vice president of venture investments for Bayer’s VC arm, Leaps by Bayer. But now, he’s the one asking for money, ... |
| 13.01.2022 | Juno co-founder launches ambitious new startup with Fred Hutch colleagues to treat cancer | From left: Affini-T scientific co-founders and Fred Hutch investigators Philip Greenberg, Aude Chapuis, and Thomas Schmitt. (Fred Hutch Photos) A new cell therapy company is on the block, propelled by powerhouse scientific co-founders from ... |
| - | 9 top West Coast biotechs that VCs say are poised to take off in the next year | Tayfun Coskun/Anadolu Agency/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months.... |
| - | Cell therapy biotech Affini-T gets $175M; KRAS is lead genomic cancer target | Cell therapy gives oncologists a powerful cancer-fighting tool, but these treatments made by engineering immune cells still have limitations. For one, their abilities in blood cancers fall short in solid tumors. Relatedly, the efficacy and ... |
| - | Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs | Tyler Le/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months. Here are the 23 companie... |
Show more